

HENRY A. WAXMAN, CALIFORNIA
EDWARD J. MARKEY, MASSACHUSETTS
RICK BOUCHER, VIRGINIA
EDOLPHUS TOWNS, NEW YORK
FRANK PALLONE, JR., NEW JERSEY
BART GORDON, TENNESSEE
BOBBY L. RUSH, ILLINOIS
ANNA G. ESHOO, CALIFORNIA
BART STUPAK, MICHIGAN
ELIOT L. ENGEL, NEW YORK
GENE GREEN, TEXAS
DIANA DEGETTE, COLORADO
VICE CHAIRMAN
LOIS CAPPS, CALIFORNIA
MIKE DOYLE, PENNSYLVANIA
JANE HARMAN, CALIFORNIA
TOM ALLEN, MAINE
JAN SCHAKOWSKY, ILLINOIS
HILDA L. SOLIS, CALIFORNIA
CHARLES A. GONZALEZ, TEXAS
JAY INSLEE, WASHINGTON
TAMMY BALDWIN, WISCONSIN
MIKE ROSS, ARKANSAS
DARLENE HOOLEY, OREGON
ANTHONY D. WEINER, NEW YORK
JIM MATHESON, UTAH
G.K. BUTTERFIELD, NORTH CAROLINA
CHARLIE MELANCON, LOUISIANA
JOHN BARROW, GEORGIA
BARON P. HILL, INDIANA
DORIS O. MATSUI, CALIFORNIA

ONE HUNDRED TENTH CONGRESS

U.S. House of Representatives
Committee on Energy and Commerce
Washington, DC 20515-6115

JOHN D. DINGELL, MICHIGAN
CHAIRMAN

JOE BARTON, TEXAS
RANKING MEMBER
RALPH M. HALL, TEXAS
FRED UPTON, MICHIGAN
CLIFF STEARNS, FLORIDA
NATHAN DEAL, GEORGIA
ED WHITFIELD, KENTUCKY
BARBARA CUBIN, WYOMING
JOHN SHIMKUS, ILLINOIS
HEATHER WILSON, NEW MEXICO
JOHN B. SHADEGG, ARIZONA
CHARLES W. "CHIP" PICKERING, MISSISSIPPI
VITO FOSSSELLA, NEW YORK
ROY BLUNT, MISSOURI
STEVE BUYER, INDIANA
GEORGE RADANOVICH, CALIFORNIA
JOSEPH R. PITTS, PENNSYLVANIA
MARY BONO MACK, CALIFORNIA
GREG WALDEN, OREGON
LEE TERRY, NEBRASKA
MIKE FERGUSON, NEW JERSEY
MIKE ROGERS, MICHIGAN
SUE WILKINS MYRICK, NORTH CAROLINA
JOHN SULLIVAN, OKLAHOMA
TIM MURPHY, PENNSYLVANIA
MICHAEL C. BURGESS, TEXAS
MARSHA BLACKBURN, TENNESSEE

June 25, 2008

DENNIS B. FITZGIBBONS, CHIEF OF STAFF
GREGG A. ROTHSCHILD, DEPUTY CHIEF OF STAFF
AND CHIEF COUNSEL

The Honorable Andrew C. von Eschenbach, M.D.
Commissioner
U.S. Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

Dear Dr. von Eschenbach:

Under Rules X and XI of the Rules of the U.S. House of Representatives, the Committee on Energy and Commerce and its Subcommittee on Oversight and Investigations have been investigating the adequacy of the efforts of the Food and Drug Administration (FDA) to protect the American public from the unnecessary risks associated with prescription drugs. We are concerned not only about the risks of drugs prescribed to treat humans, but also those administered to America's pets.

Wyeth Pharmaceuticals recalled ProHeart 6, a canine heartworm treatment, from the market in September 2004 following FDA revelations of dangerously high numbers of adverse drug event reports. In fact, serious safety problems arose in connection with ProHeart within months of its approval in June 2001. By June 2002, the label for ProHeart was amended to warn of anaphylaxix/anaphylactoid reactions, depression, lethargy, hives, and head and facial edema. In November of the same year, the label was amended again to include cardiopulmonary issues associated with heartworm-positive dogs. "Rare reports of death" was added to the label in July 2003. The FDA Veterinary Medicine Advisory Committee (VMAC), comprised of veterinary experts, also voted in 2005 that the drug was unsafe and that further studies were necessary.

Given the controversial safety record of ProHeart 6, the Committee is concerned that its return to market may be premature. Further, the public materials released in connection with FDA's announcement of ProHeart's reapproval do not adequately explain the basis of that approval. The Committee is therefore interested in learning the nature of the meetings, expertise, studies, and science that contributed ultimately to FDA's decision to reintroduce ProHeart 6 to the market.

The Honorable Andrew C. von Eschenbach, M.D.

Page 2

As a preliminary matter, the Committee seeks to find out what meetings were held to discuss ProHeart's approval, who attended the meetings, when the meetings occurred, and ultimately, the nature of the meetings.

Accordingly, we request you provide the Committee with the following documents:

1. Copies of each and every calendar day, including all entries and attachments, contained in the Microsoft Outlook calendar of Daniel G. McChesney, Ph.D.; Director of the Office of Surveillance of Compliance, the Center for Veterinary Medicine from November 1, 2004, to the date of this letter.
2. Copies of each and every calendar day, including all entries and attachments, contained in the Microsoft Outlook calendar of Aleta Sindelar, R.N., Executive Secretary of the Veterinary Medical Advisory Committee, from November 1, 2004, to the date of this letter.
3. Copies of each and every calendar day, including all entries and attachments, contained in the Microsoft Outlook calendar of Stephen Sundlof, D.V.M., Ph.D., (Former Director of the Center for Veterinary Medicine), current Director of the Center for Food Safety and Applied Nutrition, Food and Drug Administration, from November 1, 2004, to the date of this letter.
4. Copies of minutes from each and every meeting held by FDA officials and/or held between FDA officials and any third party including Wyeth representatives and/or outside experts, to evaluate ProHeart 6 beginning in September 2004, to the date of this letter.

Please supply all requested answers in electronic form within two weeks of the date of this letter. Should you have any questions relating to this request, please have your staff contact Joanne Royce or Lisa Cody with the Committee staff at (202) 226-2424.

Sincerely,



John D. Dingell
Chairman



Bart Stupak
Chairman
Subcommittee on Oversight and Investigations

The Honorable Andrew C. von Eschenbach, M.D.
Page 3

cc: The Honorable Joe Barton, Ranking Member
Committee on Energy and Commerce

The Honorable John Shimkus, Ranking Member
Subcommittee on Oversight and Investigations